All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 16, 2022
Home » Authors » Nuala Moran

Nuala Moran

Articles

ARTICLES

Euro symbol in piggy bank

Germitec raises €11M for commercialization of ultrasound probe disinfection system

May 12, 2022
By Nuala Moran
No Comments
Germitec SA has raised €11 million (US$11.6 million) to finance commercial scale-up, as it prepares to submit for FDA 510k approval of its ultrasound probe disinfection system.
Read More
Glucose testing

Type 2 diabetes getting precision medicine makeover

May 11, 2022
By Nuala Moran
No Comments
Type 2 diabetes is known to involve many different underlying mechanisms, but the considerable heterogeneity in the phenotype is mostly ignored in how it is treated. Now, researchers at University of Dundee, U.K., have developed a method for visualizing this heterogeneity and shown how the risks of complications, such as chronic kidney disease or peripheral neuropathy, differ by phenotypes.
Read More
Vaccine administration

Second booster dose increases immunity, according to Cov-Boost data

May 10, 2022
By Nuala Moran
No Comments
First results from the U.K. Cov-Boost trial, looking at responses to a fourth dose of an mRNA COVID-19 vaccine, show that antibody levels increase more than after the third dose, confirming the precautionary move to give the most vulnerable a second COVID-19 booster in advance of immune response data being available.
Read More
Silhouette made of crumpled paper illustrating depression

Proline links gut microbiome to depression

May 9, 2022
By Nuala Moran
No Comments
If it is now acknowledged the gut microbiota plays a role in the pathophysiology of depression, the specific biochemical mechanisms underlying this connection are hard to unpick and poorly understood.
Read More
Hand holding dollar sign

Orthoson closes $11M series A funding for spinal disc treatment

May 5, 2022
By Nuala Moran
No Comments
Orthoson Ltd. closed a £8.9 million (US$11.1 million) oversubscribed series A, which will be devoted to completing preparations for its ultrasound/hydrogel combination treatment for repairing degenerated spinal discs to start phase I clinical trials.
Read More
T cells
Newco news

Engimmune raises $16.7M in seed round to build better T-cell receptors

May 3, 2022
By Nuala Moran
No Comments
Engimmune Therapeutics AG has raised CHF15.5 million (US$16.7 million) in a seed round, as it prepares to address efficacy and safety shortcomings that currently constrain T-cell receptor and soluble TCR cancer therapies. The Basel, Switzerland-based company’s technology brings together genome editing, functional screening, deep mutational sequencing and machine learning, to engineer synthetic T-cell receptors that are highly specific to a chosen tumor antigen, increasing affinity and safety and avoiding off-target effects.
Read More
Cancer cell and DNA

To escape radiation, tumor cells reversibly damage their DNA

May 2, 2022
By Nuala Moran
No Comments
Researchers have uncovered a new pathway via which cancer cells evade the effects of radiation by deploying self-inflicted – but reversible – DNA breaks to stop the cell cycle and ensure their survival. The lesions are caused by caspase-activated DNase (CAD), an enzyme involved in DNA fragmentation during cell death. In response to radiation, tumor cells activate CAD, causing genome-wide DNA breaks at sites involved in DNA repair.
Read More
FDA approved icons and medical professional

Orphalan wins US FDA approval for Wilson’s disease drug Cuvrior

May 2, 2022
By Nuala Moran
No Comments
Orphalan SA is laying the ground for a 2023 U.S. launch of Cuvrior for the treatment of Wilson’s disease, following FDA approval of the copper chelating drug. Cuvrior (trientine tetrahydrochloride) is a new salt of trientine that was designed to have superior properties to Syprine (trientine hydrochloride) from Bausch Health Companies Inc. and Cufence from Univar Solutions BV, which are approved as second-line treatments for the rare inherited copper transport disorder, in the U.S. and EU respectively.
Read More
Cancer cell and DNA

To escape radiation, tumor cells reversibly damage their DNA

April 29, 2022
By Nuala Moran
No Comments
Researchers have uncovered a new pathway via which cancer cells evade the effects of radiation by deploying self-inflicted – but reversible – DNA breaks to stop the cell cycle and ensure their survival.
Read More
Ros Deegan, CEO, Omass Therapeutics

No ‘easy targets’ for Omass, which adds $95M series B for small-molecule work

April 28, 2022
By Nuala Moran
No Comments
Omass Therapeutics Ltd. has raised £75.5 million (US$94.6 million) in a series B round, as it continues to advance five small-molecule programs against previously intractable membrane-bound targets to the clinic.
Read More
View All Articles by Nuala Moran

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 13, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for May 13.
  • Hearing ear icon

    Cochlear to acquire rival Oticon Medical for $121M

    BioWorld MedTech
    Cochlear Ltd. will acquire Danish hearing implant company Oticon Medical A/S for AU$170 million (US$121 million) after parent company the Demant Group said it...
  • Illustration of cancer cells and immunotherapy treatment

    Former Genentech execs launch new immunotherapy biotech LTZ Therapeutics

    BioWorld
    After raising $17 million in seed funding, immunotherapy-focused biotech company, LTZ Therapeutics Inc., is announcing plans for the fledgling company whose...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing